Baseline Characteristics and Prior Treatments
| Characteristic | Data (n = 66) |
|---|---|
| Age (y) | 74 (68–78) |
| Baseline PSA (ng/mL) | 109 (33–290) |
| Baseline hemoglobin (g/L) | 11.3 (9.95–12.5) |
| Baseline white blood cell count (109/L) | 6 (4.6–7.4) |
| Baseline platelet count (109/L) | 212 (180–264.75) |
| Baseline lactate dehydrogenase (U/L) | 201.5 (155–278.75)* |
| Gleason score | 8 (7–9)† |
| Eastern Cooperative Oncology Group score | |
| 0–1 | 55/66 (83%) |
| 2 | 11/66 (17%) |
| Prostatectomy | 23/66 (35%) |
| Prior curative-intent radiotherapy | 17/66 (25%) |
| Androgen receptor pathway inhibitor regimens (n) | 66/66 (100%) |
| 1 | 21/66 (32%) |
| ≥2 | 45/66 (68%) |
| Chemotherapy regimens (n) | 61/66 (92%) |
| 0 | 5/66 (8%) |
| 1 | 30/66 (45%) |
| ≥2 | 31/66 (47%) |
| Olaparib | 8/66 (12%) |
| 223Ra | 9/66 (14%) |
| Sipuleucel-T | 21/66 (32%) |
| Number of LuPSMA cycles | 4.5 (3–6) |
| Bone | 61/66 (92%) |
| Prostate/surgical site | 21/66 (32%) |
| Lymph nodes | 35/66 (53%) |
| Viscera | 16/66 (24%) |